Predicate |
Object |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-065 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12S3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
filingDate |
1997-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate |
2001-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
JP-2001504092-A |
titleOfInvention |
Method for producing an IgM formulation for intravenous application |
abstract |
(57) [Summary]nIn a method of preparing an immunoglobulin solution suitable for intravenous application, wherein the IgM content is greater than 5% by weight of the immunoglobulin, the IgM-containing immunoglobulin solution is treated with a protease. The resulting intravenous compatible formulation is characterized by being chemically unmodified and exhibiting low anti-complement activity ACA. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005035574-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8920797-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7803914-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8257703-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7709615-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016196477-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013530950-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013531630-A |
priorityDate |
1996-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |